Inhibrx Biosciences, Inc.
INBX
$14.00
$0.000.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -88.89% | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -88.89% | -- | -- | -- | |
| Cost of Revenue | 6.32% | -- | -- | -- | |
| Gross Profit | -7.22% | -- | -- | -- | |
| SG&A Expenses | 103.93% | -- | -- | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 19.28% | -- | -- | -- | |
| Operating Income | -20.17% | -- | -- | -- | |
| Income Before Tax | 799.20% | -- | -- | -- | |
| Income Tax Expenses | -33.33% | -- | -- | -- | |
| Earnings from Continuing Operations | 799.19% | -- | -- | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 799.19% | -- | -- | -- | |
| EBIT | -20.17% | -- | -- | -- | |
| EBITDA | -19.77% | -- | -- | -- | |
| EPS Basic | 673.67% | -- | -- | -- | |
| Normalized Basic EPS | 8.09% | -- | -- | -- | |
| EPS Diluted | 665.61% | -- | -- | -- | |
| Normalized Diluted EPS | 8.80% | -- | -- | -- | |
| Average Basic Shares Outstanding | 25.62% | -- | -- | -- | |
| Average Diluted Shares Outstanding | 26.02% | -- | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |
